| Year | Q2 2024 | Q1 2024 |
|---|---|---|
| Total Revenue | 4.58B | 5.55B |
| Cost of Revenue | 2.94B | 3.98B |
| Gross Profit | 1.64B | 1.58B |
| Operating Expenses | 910.46M | 815.58M |
| Research and Development | 0 | 0 |
| Selling, General & Administrative Expenses | 910.46M | 815.58M |
| Selling & Marketing Expenses | 0 | 0 |
| General & Administrative Expenses | 0 | 0 |
| Other Expenses | 0 | 22.16M |
| Operating Income | 727.9M | 762.93M |
| Total Other Income/Expenses Net | -10.23M | -26.17M |
| Income Before Tax | 717.68M | 736.77M |
| Income Tax | 171.45M | 182.23M |
| Net Income | 546.23M | 554.54M |
| Basic EPS | 6.03 | 6.12 |
| EPS Diluted | 6.02 | 6.12 |
| Basic Average Shares | 90.58M | 90.63M |
| Diluted Average Shares | 90.74M | 90.63M |
| EBITDA | 981.56M | 986.77M |
Aarti Pharmalabs Limited
AARTIPHARM.NS
NSE
679.4INR55 (-0.25%)
AARTIPHARM.NS Financial Statements
Retained Earning Schedule
| Year |
|---|
| Retained Earnings (Previous Year) |
| Net Income |
| Stock Repurchases |
| Dividend Paid |
| Retained Earnings |
| Other Distributions |
PPE Schedule
| Year |
|---|
| Gross PPE |
| Annual Depreciation |
| Capital Expenditure |
| Net PPE |
Intangible and Goodwill Schedule
| Year |
|---|
| Acquisitions and Adjustments |
| Goodwill (Previous Year) |
| Goodwill |